MediPharm Labs Corp. (TSX:LABS)
Canada · Delayed Price · Currency is CAD 0.0800
0.00 (0.00%)
Aug 28, 2026, 9:52 AM EST
MediPharm Labs Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 41.46 | 45.12 | 41.96 | 33.06 | 22.12 | 21.71 | |
Revenue Growth | -6.74% | 7.54% | 26.92% | 49.49% | 1.87% | -39.71% |
Cost of Revenue | 28.31 | 31.26 | 29.27 | 24.96 | 24.19 | 35.13 |
Gross Profit | 13.14 | 13.86 | 12.69 | 8.1 | -2.07 | -13.42 |
Selling, General & Admin | 16.6 | 20.73 | 21.96 | 21.07 | 24.4 | 30.87 |
Research & Development | 0.21 | 0.22 | 0.32 | 0.29 | 1.12 | 1.51 |
Other Operating Expenses | 0.32 | 0.17 | 0.26 | 0.07 | 0.17 | -0.07 |
Operating Expenses | 17.09 | 21.08 | 22.62 | 21.42 | 25.7 | 32.3 |
Operating Income | -3.94 | -7.22 | -9.94 | -13.32 | -27.77 | -45.72 |
Interest Expense | -0.06 | -0.06 | -0.58 | -0.37 | -0.03 | -10.51 |
Interest & Investment Income | 0.23 | 0.23 | 0.69 | 0.84 | 0.48 | 0.23 |
Currency Exchange Gain (Loss) | -0.04 | -0.04 | 0.05 | -0.46 | -0.74 | -1.67 |
Other Non Operating Income (Expenses) | - | - | - | - | 0 | 4.51 |
EBT Excluding Unusual Items | -3.81 | -7.09 | -9.78 | -13.3 | -28.06 | -53.16 |
Merger & Restructuring Charges | -1.25 | -1.19 | -0.96 | -4.42 | -1.04 | - |
Gain (Loss) on Sale of Assets | 0.12 | 0.12 | 0.3 | -0.08 | -0.91 | - |
Asset Writedown | -0.03 | -0.12 | -0.26 | -0.22 | - | -6.29 |
Other Unusual Items | - | - | - | 4.67 | 0.02 | 4.76 |
Pretax Income | -4.97 | -8.27 | -10.69 | -13.36 | -29.99 | -54.69 |
Income Tax Expense | - | - | - | -0.28 | -0.01 | 0.11 |
Earnings From Continuing Operations | -4.97 | -8.27 | -10.69 | -13.08 | -29.98 | -54.8 |
Net Income | -4.97 | -8.27 | -10.69 | -13.08 | -29.98 | -54.8 |
Net Income to Common | -4.97 | -8.27 | -10.69 | -13.08 | -29.98 | -54.8 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 423 | 418 | 408 | 363 | 277 | 250 |
Shares Outstanding (Diluted) | 423 | 418 | 408 | 363 | 277 | 250 |
Shares Change | 2.31% | 2.53% | 12.29% | 31.23% | 10.79% | 80.37% |
EPS (Basic) | -0.01 | -0.02 | -0.03 | -0.04 | -0.11 | -0.22 |
EPS (Diluted) | -0.01 | -0.02 | -0.03 | -0.04 | -0.11 | -0.22 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -1.04 | -5.6 | -5.02 | -12.81 | -16.93 | -14 |
Free Cash Flow Per Share | -0.00 | -0.01 | -0.01 | -0.04 | -0.06 | -0.06 |
Gross Margin | 31.70% | 30.71% | 30.24% | 24.50% | -9.38% | -61.81% |
Operating Margin | -9.51% | -16.00% | -23.68% | -40.30% | -125.56% | -210.59% |
Profit Margin | -12.00% | -18.32% | -25.49% | -39.57% | -135.56% | -252.41% |
Free Cash Flow Margin | -2.52% | -12.42% | -11.95% | -38.75% | -76.56% | -64.46% |
EBITDA | -2.41 | -5.59 | -7.4 | -10.92 | -24.99 | -40.42 |
EBITDA Margin | -5.82% | -12.40% | -17.64% | -33.02% | -112.99% | -186.17% |
D&A For EBITDA | 1.53 | 1.63 | 2.54 | 2.41 | 2.78 | 5.3 |
EBIT | -3.94 | -7.22 | -9.94 | -13.32 | -27.77 | -45.72 |
EBIT Margin | -9.51% | -16.00% | -23.68% | -40.30% | -125.56% | -210.59% |
Revenue as Reported | 41.46 | 45.12 | 41.96 | 33.06 | 22.12 | - |
Advertising Expenses | - | 0.8 | 0.87 | 1.27 | - | - |